Cryo-Cell Reports Stable Revenue and Higher Profit in Fiscal Q3 2026
Published in Financial, Organisations.
Publication date: October 9, 2026.
Cryo-Cell International released its fiscal third-quarter results on October 9, providing an updated view of a company operating in cord blood and cord tissue cryopreservation. The reporting period ended August 31, 2026.
The company reported consolidated revenue of US$7.82 million, compared with US$7.83 million in the corresponding quarter of 2025. Net income increased to US$1.27 million from US$749,000, while basic and diluted earnings per share rose to US$0.16 from US$0.09.
The figures indicate nearly unchanged quarterly revenue alongside higher reported profit. The announcement does not provide enough detail to attribute that difference to a particular operational improvement or to establish a continuing trend.
According to Cryo-Cell, it and its global affiliates store more than 250,000 cord blood and cord tissue specimens. The company also describes a public banking partnership with Duke University and says its public bank has supplied cord blood for more than 900 transplants.
This announcement concerns financial performance and banking operations; it reports no new clinical trial results or newly approved regenerative treatment.